Compositions, methods, and applications of a synthetic surfactant

A pulmonary drug delivery composition comprising a synthetic Tungara frog foam, the synthetic Tungara frog foam comprising a plurality of synthetically synthesized ranaspumin proteins (RSN), wherein (i) only active segments of the RSN proteins are synthesized and signal peptides are effectively removed, (ii) wherein the ranaspumin proteins (RSN) comprise six synthetically synthesized ranaspumin proteins, comprising:

• ranaspumin-1 (RSN-1) comprising the amino acid sequence as set forth in SEQ ID NO:
• 1;
• ranaspumin-2 (RSN-2) comprising the amino acid sequence as set forth in SEQ ID NO:
• 2;
• ranaspumin-3 (RSN-3) comprising the amino acid sequence as set forth in SEQ ID NO:
• 3;
• ranaspumin-4 (RSN-4) comprising the amino acid sequence as set forth in SEQ ID NO:
• 4;
• ranaspumin-5 (RSN-5) comprising the amino acid sequence as set forth in SEQ ID NO:
• 5;
• and,
• ranaspumin-6 (RSN-6) comprising the amino acid sequence as set forth in SEQ ID NO:
• 6 and
• (iii) wherein the synthetic Tungara frog foam further comprises a sugar backbone, (iv) wherein synthesis of only the active segments of the RSN proteins results in proper folding of the protein and allows surfactant capabilities to be retained in the synthetic foam, and (v) wherein the synthetic foam maintains stability for greater than 10 days without any dehydration or loss of foam structure due to surface tension effects.